TreatSMA

Shielding Guidance extended until 31st March 2021.

Shielding guidance for those who are clinically extremely vulnerable has been extended now until the 31st March 2021, instead of the previous date given 21st February 2021.

You should receive an email and/or a letter to confirm this which can be used as evidence for employers or DWP including for Statuary Sick Pay, (SSP) and Employment Support Allowance, (ESA). If you do not receive a letter or email, and have previously been told to shield, please contact your GP and make sure your GP and consultants have all up to date information for the relevant shielding person.

Please see link below for further advice:

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more